PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media280009ArticlesСтатьиResearch ArticleAdjuvant hormonal therapy in perimenopausal women with ER-positive breast cancerАдъювантная гормонотерапия женщин в перименопаузе с РЭ-положительным раком молочной железыSemiglazovV. FСемиглазовВ. Ф

д.м.н., профессор, член-корр. РАМН

SemiglazovV. VСемиглазовВ. В

д.м.н.

НИИ онкологии им. Н.Н. ПетроваСПбГМУ им. акад. И.П. Павлова200920121918NO18 (2012)№18 (2012)717524022023Copyright ©; 2012, Bionika MediaCopyright ©; 2012, ООО «Бионика Медиа»2012Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/280009

In patients with hormone-sensitive breast cancer and clinical or biochemical signs of ovarian estrogen synthesis, the use of aromatase inhibitors is contraindicated. Pre- and posttreatment measurement of estradiol and follicle-stimulating hormone levels should be performed in women receiving aromatase inhibitors, who are not clearly postmenopausal, or have the risk of resumption of ovarian function. The uses of tamoxifen in perimenopausal women, suppression of ovarian function (SOF) or a combination of POF with tamoxifen remain the standard adjuvant hormonal therapy strategies.

Для больных гормоночувствительным первичным раком молочной железы, имеющих клинические или биохимические признаки синтеза овариальных эстрогенов, применение ингибиторов ароматазы противопоказано. Измерение уровней эстрадиола и фолликулостимулирующего гормона должно быть проведено до и во время лечения ингибиторами ароматазы женщинам, не являющимся явно постменопаузальными или имеющими риск возобновления овариальной функции. Применение женщинами в перименопаузе тамоксифена, подавление овариальной функции (ПОФ) или комбинация ПОФ с тамоксифеном все еще остаются стандартной стратегией адъювантной гормонотерапии.

breast cancerperimenopausehormone therapysuppression of ovarian functionрак молочной железыперименопаузагормонотерапияподавление овариальной функцииСемиглазов В.Ф., Семиглазов В.В., Дашян Г.А. Эндокринотерапия раннего рака молочной железы. Руководство. М., 2011. 96 с.Семиглазов В.Ф., Семиглазов В.В., Манихас А.Г. Рак молочной железы. Химиотерапия и таргетная терапия. М., 2012. 360 с.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer Res. Treat 2008;2.Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2005. J Clin Oncol 2005;23:619-29.Miller W.R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30:3-11.Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-42.Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444-47.Burstein H.J., Mayer E., Partridge A.H., et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006;7:158-61.Fallowfield L. Quality of life of postmenopausal women in the ATAC trial. J Clin Oncol 2004;22:4261-71.Henrich J.B., Hughes J.P., Kaufman S.C., Brody D.J., Curtin L.R. Limitations of follicle-stimulating hormone in assessing menopause status: findings from the National Health and Nutrition Examination Survey (NHANES 1999-2000). Menopause 2006;13:171-77.Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-39.Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.Thurliman B. A comparison of letrozole and tamoxifen in postmenopausal women in early breast cancer. N Engl J Med 2005;353:2747-57.Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian TamoxifenAnastrozole Trial. J Clin Oncol 2005;23:5138-47.Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.Gracia C.R., Sammel M.D., Freeman E.W., et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005;12;128-35.Smith-DiJulio K., Mitchell E.S., Woods N.F. Concordance of retrospective and prospective reporting of menstrual irregularity by women in the menopausal transition. Climacteric 2005;8:390-97.Clemons M., Simmons C. Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat 2007;104:115-20.Minton S.E., Munster P.N. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466-72.Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769-79.Klijn J.G., Blamey R.W., Boccardo F., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.Celio L., Martinetti A., Ferrari L., et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999;19:2261-68.Parulekar W.R., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 2005;23:6002-08.Recchia F., Saggio G., Amiconi G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23.Jannuzzo M.G., Di Salle E., Spinelli R., et al. Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women. J Clin Oncol 2004;22(14S):2041.Carlson R. Goserelin plus anastrozole for treatment of premenopausal women with hormone receptor positive recurrent/metastatic breast cancer [Abstract]. Breast Cancer Res Treat 2004;88(1):S237-38.Hargis J.B., Nakajima S.T. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest 2006;24:174-77.Duggan C., Marriott K., Edwards R., Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588-93.Gradishar W.J. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;691-99.